PURPOSE: To evaluate the impact of surgical waiting time (SWT) on outcomes of patients who underwent radical nephrectomy for stage II or higher renal cell carcinoma (RCC). METHODS: Of the 1,732 patients who underwent surgery for RCC between 1989 and 2007, medical records of 319 with clinical stage II or higher RCC without distant metastases were retrospectively reviewed. Ten patients with SWT greater than 3 months were excluded from analysis, and we compared pathological upstaging and survival rates between patients with SWT <1 month (234/319, 73.3 %) and 1-3 months (75/319, 23.5 %). RESULTS: Clinicopathological characteristics between two groups were not different except the presence of symptom. The pathological upstaging was higher in patients with SWT of 1-3 months but statistically not significant. SWT of 1-3 months was not an independent predictor of pathological upstaging, recurrence-free survival (RFS; p = 0.896), or cancer-specific survival (CSS; p = 0.737). On subgroup analysis by TNM stage (cT2NxcM0 and cT3-4NxcM0), SWT of 1-3 months was not an independent predictor of pathological upstaging and was not associated with RFS or CSS. SWT, treated as a continuous variable, was also not an independent predictor of outcome in any subgroup. Similar results were found in symptomatic patients. CONCLUSIONS: The outcomes of patients with prolonged SWT did not differ from those of most patients who underwent nephrectomy within 1 month. In patients with stage II or higher RCC who underwent nephrectomy within 3 months after diagnosis, prolonged SWT was not an independent predictor of pathological upstaging, RFS, or CSS.
PURPOSE: To evaluate the impact of surgical waiting time (SWT) on outcomes of patients who underwent radical nephrectomy for stage II or higher renal cell carcinoma (RCC). METHODS: Of the 1,732 patients who underwent surgery for RCC between 1989 and 2007, medical records of 319 with clinical stage II or higher RCC without distant metastases were retrospectively reviewed. Ten patients with SWT greater than 3 months were excluded from analysis, and we compared pathological upstaging and survival rates between patients with SWT <1 month (234/319, 73.3 %) and 1-3 months (75/319, 23.5 %). RESULTS: Clinicopathological characteristics between two groups were not different except the presence of symptom. The pathological upstaging was higher in patients with SWT of 1-3 months but statistically not significant. SWT of 1-3 months was not an independent predictor of pathological upstaging, recurrence-free survival (RFS; p = 0.896), or cancer-specific survival (CSS; p = 0.737). On subgroup analysis by TNM stage (cT2NxcM0 and cT3-4NxcM0), SWT of 1-3 months was not an independent predictor of pathological upstaging and was not associated with RFS or CSS. SWT, treated as a continuous variable, was also not an independent predictor of outcome in any subgroup. Similar results were found in symptomatic patients. CONCLUSIONS: The outcomes of patients with prolonged SWT did not differ from those of most patients who underwent nephrectomy within 1 month. In patients with stage II or higher RCC who underwent nephrectomy within 3 months after diagnosis, prolonged SWT was not an independent predictor of pathological upstaging, RFS, or CSS.
Authors: Nicholas J Hellenthal; Willie Underwood; Remedios Penetrante; Alan Litwin; Shaozeng Zhang; Gregory E Wilding; Bin T Teh; Hyung L Kim Journal: J Urol Date: 2010-09 Impact factor: 7.450
Authors: Martin Nuttall; Paul Cathcart; Jan van der Meulen; David Gillatt; Gregor McIntosh; Mark Emberton Journal: BJU Int Date: 2005-07 Impact factor: 5.588
Authors: Ross J Mason; Mohamed Abdolell; Greg Trottier; Christopher Pringle; Joseph G Lawen; David G Bell; Michael A S Jewett; Laurence Klotz; Ricardo A Rendon Journal: Eur Urol Date: 2011-02-22 Impact factor: 20.096
Authors: Carlos H Martínez; Paul Martin; Venu Chalasani; Andrew K Williams; Patrick P W Luke; Jonathan I Izawa; Joseph L Chin; Larry Stitt; Stephen E Pautler Journal: Can Urol Assoc J Date: 2011-03-01 Impact factor: 1.862
Authors: Soroush Rais-Bahrami; Thomas J Guzzo; Thomas W Jarrett; Louis R Kavoussi; Mohamad E Allaf Journal: BJU Int Date: 2009-02-23 Impact factor: 5.588
Authors: Anil A Thomas; Brian I Rini; Brian R Lane; Jorge Garcia; Robert Dreicer; Eric A Klein; Andrew C Novick; Steven C Campbell Journal: J Urol Date: 2008-12-18 Impact factor: 7.450
Authors: Stephen J Freedland; Christopher J Kane; Christopher L Amling; William J Aronson; Joseph C Presti; Martha K Terris Journal: J Urol Date: 2006-04 Impact factor: 7.450
Authors: Roy Mano; Emily A Vertosick; Abraham Ari Hakimi; Itay A Sternberg; Daniel D Sjoberg; Melanie Bernstein; Guido Dalbagni; Jonathan A Coleman; Paul Russo Journal: Urol Oncol Date: 2016-01-12 Impact factor: 3.498
Authors: Sudeh Izadmehr; Dara J Lundon; Nihal Mohamed; Andrew Katims; Vaibhav Patel; Benjamin Eilender; Reza Mehrazin; Ketan K Badani; John P Sfakianos; Che-Kai Tsao; Peter Wiklund; William K Oh; Carlos Cordon-Cardo; Ashutosh K Tewari; Matthew D Galsky; Natasha Kyprianou Journal: Front Oncol Date: 2021-09-27 Impact factor: 6.244
Authors: Arnav Srivastava; Hiren V Patel; Sinae Kim; Brian Shinder; Joshua Sterling; Alexandra L Tabakin; Charles F Polotti; Biren Saraiya; Tina Mayer; Isaac Y Kim; Saum Ghodoussipour; Hiten D Patel; Thomas L Jang; Eric A Singer Journal: Urol Oncol Date: 2020-10-20 Impact factor: 3.498
Authors: Denise Garcia; Julie B Siegel; David A Mahvi; Biqi Zhang; David M Mahvi; E Ramsay Camp; Whitney Graybill; Stephen J Savage; Antonio Giordano; Sara Giordano; Denise Carneiro-Pla; Mahsa Javid; Aaron P Lesher; Andrea Abbott; Nancy Klauber DeMore Journal: Clin Oncol Res Date: 2020-06-26